Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

Genmab Reports Financial Results for the 12 Months Ended December 31, 2007

COPENHAGEN, Denmark, March 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the financial year ended December 31, 2007.

Revenues of DKK 530 million (approximately USD 104 million) compared to DKK 136 million (approximately USD 27 million) in 2006.

An Operating Loss of DKK 437 million (approximately USD 86 million). This compares to an Operating Loss of DKK 472 million (approximately USD 93 million) reported in 2006.

Net Financial Income totaled DKK 54 million (approximately USD 11 million) compared to Net Financial Income of DKK 34 million (approximately USD 7 million) in 2006.

A Net Loss of DKK 383 million (approximately USD 76 million) compared to a Net Loss in 2006 of DKK 438 million (approximately USD 86 million). The Net Loss per share was DKK 8.72 (approximately USD 1.72) in 2007 compared to a Net Loss per share of DKK 11.26 (approximately USD 2.22) in 2006. The 2007 Net Loss exceeded Genmab's guidance of DKK 260 to 310 million as a development milestone payment projected for late 2007 was not received until January 2008. The milestone payment of DKK 87 million was triggered by the first patient receiving treatment in the HuMax-CD20 (ofatumumab) Phase III rheumatoid arthritis (RA) program.

Genmab ended the year with a cash position of DKK 3.7 billion (approximately USD 728 million), which is an increase of approximately DKK 2.0 billion (approximately USD 388 million) from the end of 2006.

USD 1.00 = DKK 5.075 (Danish Central Bank's spot rate on December 31, 2007)

2007 Highlights:

Genmab achieved a number of business and scientific milestones, as follows:

Partnership progress:

Genmab and GlaxoSmithKline received antitrust clearance for the

HuMax-CD20 co-development and commercialization agreement; achieved first

two milestones in collaboration

Achieved
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... -- Lancée par l,Assistance Publique ... en décembre 2011, l,étude collaborative française randomisée et ...   l es microsphères en résine marquées ... carcinome hépatocellulaire avancé, a recruté plus de 400 ... ; les résultats sont attendus fin 2016.   ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... 18 Novavax, Inc. (Nasdaq: NVAX ) a ... and Chief Executive Officer, will be presenting at the Phacilitate ... 23, 2009 at The Fira Palace, Barcelona, Spain. Dr. ... VLP based vaccines helping to shape the manufacturing processes of ...
... (NYSE: BSX ) is scheduled to participate in ... 24. , , Jim Tobin, President and Chief Executive ... beginning at approximately 9:00 a.m. E.T. Following the presentation, ... join Mr. Tobin in a question and answer session. , ...
... ,Funding Biopharma: Strategies for Reaching Investors in a Financial ... , BASKING RIDGE, N.J., June 18 Biotech companies ... with half of the industry,s 370 small-cap funds slated ... executives and investment market leaders concluded during a life ...
Cached Biology Technology:Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of the "Global Biometrics Market ... offering. The market for biometric authentication ... of around 14% till 2020 The ... be increasing security needs, government projects and constant ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... , March 2, 2015 Synaptics ... developer of human interface solutions, today announced a ... is designed to enable rapid and secure transactions ... module for gaming is a turnkey solution providing ... ability to quickly integrate fingerprint ID solutions into ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... million in U.S. dollars have been awarded to ... studies related to asthma and other immune system ... extramural grants were awarded by the Biomedical Research ... and Research), the government agency driving Singapore,s transformation ...
... Gary G. Borisy, director and CEO of the MBL ... Academy of Sciences (NAS), an honorific society of distinguished ... considered one of the highest honors in American science ... annual meeting in Washington, D.C. Dr. Borisy is one ...
... of mutually beneficial arrangements between organismslike the relationship ... sometimes these blissful relationships have a dark side, ... article for the May issue of The ... ants and plants is a great example of ...
Cached Biology News:Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 3Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 4MBL director and CEO and cell biology pioneer Gary Borisy elected to National Academy of Sciences 2MBL director and CEO and cell biology pioneer Gary Borisy elected to National Academy of Sciences 3When industrious ants go too far 2
... The Rotofor purification system with PowerPac ... for protein separation and purification by liquid-phase ... the mini (18 ml) and standard (60 ... finger, electrode chambers, PowerPac 3000 power supply, ...
... The Bio-Rad Molecular Imager VersaDoc MP ... quantitative CCD based imaging system capable ... detection methods, including fluorescence, chemiluminescence, densitometry, ... Blue illumination sources allow imaging of ...
...
...
Biology Products: